Dr. Bruix Discusses Progress of Second-Line Treatment in HCC

Jordi Bruix, MD
Published: Monday, Jul 10, 2017



Jordi Bruix, MD, head of the Barcelona Clinic Liver Cancer (BCLC) at University of Barcelona, discusses the impact of the recent progress in the second-line treatment setting for hepatocellular carcinoma (HCC).

With the FDA approval of regorafenib (Stivarga) for patients with HCC who have progressed on prior sorafenib (Nexavar) treatment, this once dismal disease landscape has been reinvigorated.

These advancements, says Bruix, are extremely beneficial for the patients—but also for physicians and the community, who had felt there was no hope in treatment beyond sorafenib.
 
SELECTED
LANGUAGE


Jordi Bruix, MD, head of the Barcelona Clinic Liver Cancer (BCLC) at University of Barcelona, discusses the impact of the recent progress in the second-line treatment setting for hepatocellular carcinoma (HCC).

With the FDA approval of regorafenib (Stivarga) for patients with HCC who have progressed on prior sorafenib (Nexavar) treatment, this once dismal disease landscape has been reinvigorated.

These advancements, says Bruix, are extremely beneficial for the patients—but also for physicians and the community, who had felt there was no hope in treatment beyond sorafenib.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Addressing Post-Transplant Obstacles: Current and Emerging Strategies to Evolve the Standard of Care for Patients With Graft-Versus-Host DiseaseMar 28, 20192.0
2017 Year in Review™: Clinical Impact of Immunotherapies in the Treatment of CancerMar 30, 20191.75
Publication Bottom Border
Border Publication
x